Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin

Cancer Gene Therapy

Volumn 12, Issue 7, 2005, Pages 655-662

  Greco, Olga ^a   Powell, Tanya M ^a   Marples, Brian ^a   Joiner, Michael C ^a   Scott, Simon D ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adriamycin; GFP; HSVtk GCV; Radiation

Indexed keywords

CISPLATIN; CYTOTOXIN; DOXORUBICIN; EARLY GROWTH RESPONSE FACTOR 1; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; PRODRUG; THYMIDINE KINASE;

ARTICLE; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG POTENTIATION; EGR1 GENE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GLIOBLASTOMA; GROWTH INHIBITION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NEUTRON RADIATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; RADIATION DOSE; REPORTER GENE; SIDE EFFECT; SUICIDE GENE THERAPY; TRANSGENE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; APOPTOSIS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; DOXORUBICIN; EARLY GROWTH RESPONSE PROTEIN 1; GANCICLOVIR; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIOBLASTOMA; GREEN FLUORESCENT PROTEINS; HUMANS; IMMEDIATE-EARLY PROTEINS; NEUTRONS; PROMOTER REGIONS (GENETICS); RADIATION-SENSITIZING AGENTS; RESPONSE ELEMENTS; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; ZINC FINGERS;

MINK CELL FOCUS-FORMING VIRUS; SIMPLEXVIRUS;

EID: 22044442810     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700834     Document Type: Article

References (52)

1. Forman JD, Yudelev M, Bolton S, Tekyi-Mensah S, Maughan R. Fast neutron irradiation for prostate cancer. Cancer Metastasis Rev. 2002;21:131-135.
2. Auberger T, Reuschel W. The role of fast neutrons in the treatment of squamous cell carcinomas of the head and neck: The European experience. Recent Results Cancer Res. 1998;150:137-147.
3. Grigsby PW. Radiation Therapy Oncology Group clinical trials for carcinoma of the cervix. Int J Gynecol Cancer. 1999;9:439-447.
4. Schwarz R, Krull A, Lessel A. et al. European results of neutron therapy in soft tissue sarcomas. Recent Results Cancer Res. 1998;150:100-112.
5. Catterall M, Errington RD, Bewley DK. Fast neutrons in the treatment of locally advanced breast cancer. Eur J Surg Oncol. 1987;13:315-319.
6. Halpern J, Maor MH, Hussey DH, Henkelmann GC, Sampiere V, McNeese MD. Locally advanced breast cancer treated with neutron beams: long-term follow-up in 28 patients. Int J Radial Oncol Biol Phys, 1990;18:825-831.
7. Griffin T, Pajak T, Laramore G, Davis L. Analysis of neutron radiotherapy treatment complications. Bull Cancer. 1986;73:582-586.
8. Scott SD, Greco O. Radiation and hypoxia inducible gene therapy systems. Cancer Metastasis Rev. 2004;23:269-276.
9. Maughan RL, Blosser GF, Blosser EB, et al. A multirod collimator for neutron therapy. Im J Radiat Oncol Biol Phys. 1996;34:411-420.
10. Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med. 1995;1:786-791.
11. Weichselbaum RR, Hallahan DE, Beckett MA, et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 1994;54:4266-4269.
12. Joki T, Nakamura M, Ohno T. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum Gene Ther. 1995;6:1507-1513.
13. Senzer N, Mani S, Rosemurgy A, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004;22:592-601.
14. Datta R, Rubin E. Sukhatme V, et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci USA. 1992;89:10149-10153.
15. Datta R, Taneja N, Sukhatme VP, Qureshi SA, Weichselbaum R, Kufe DW. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci USA. 1993;90:2419-2422.
16. Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP. Development of synthetic promoters for radiation-mediated gene therapy. Gene Therapy. 2000;7:511-517.
17. Scott SD, Joiner MC, Marples B. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Therapy. 2002;9:1396-1402.
18. Scott SD, Marples B, Hendry JH, et al. A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Therapy. 2000;7:1121-1125.
19. Greco O, Marples B, Dachs GU, Williams KJ, Patterson AV, Scott SD. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Therapy. 2002;9:1403-1411.
20. Park JO, Lopez CA, Gupta VK, et al. Transcriptional control of viral gene therapy by cisplatin. J Clin Invest. 2002;110:403-410.
21. Quinones A, Dobberstein KU, Rainov NG. The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells. Life Sci. 2003;72:2975-2992.
22. Saadane N, Alpert L, Chalifour LE. TAFII250, Egr-1, and D-type cyclin expression in mice and neonatal rat cardiomyocytes treated with doxorubicin. Am J Physiol. 1999;216: H803-H814.
23. Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev. 2004;30:53-81.
24. Biganzoli L, Minisini A, Aapro M, Di Leo A. Chemotherapy for metastatic breast cancer. Curr Opin Obstet Gynecol. 2004;16:37-41.
25. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther. 2003;3:13-26.
26. Teh BS, Aguilar-Cordova E, Kernen K, et al. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer-a preliminary report. Int J Radiat Oncol Biol Phys. 2001;51:605-613.
27. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002;62:4968-4976.
28. Parada C, Hernandez Losa J, Guinea J, et al. Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system. Cancer Gene Ther. 2003;10:152-160.
29. Tong X, Shine DH, Agoulnik I, et al. Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents. Anticancer Res. 1998;18:3421-3426.
30. Maughan RL, Powers WE, Blosser HG. A superconducting cyclotron for neutron radiation therapy. Med Phys. 1994;21:779-785.
31. Krull A, Schwarz R, Brackrock S, et al. Neutron therapy in malignant salivary gland tumors: results at European centers. Recent Results Cancer Res. 1998;150:88-99.
32. Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA. 1996;93:3525-3529.
33. Kokoris MS, Sabo P, Adman ET, Black ME. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Therapy. 1999;6:1415-1426.
34. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol. 2002;193:287-292.
35. Meyer RG, Kupper JH, Kandolf R, Rodemann HP. Early growth response-1 gene (Egr-1) promoter induction by ionizing radiation in U87 malignant glioma cells in vitro. Eur J Biochem. 2002;269:337-346.
36. Britten RA, Peters LJ, Murray D. Biological factors influencing the RBE of neutrons: implications for their past, present and future use in radiotherapy. Radiat Res. 2001;156:125-135.
37. Barendsen GW. RBE-LET relationships for different types of lethal radiation damage in mammalian cells: comparison with DNA dsb and an interpretation of differences in radiosensitivity. Int J Radiat Biol. 1994;66:433-436.
38. Goodhead DT. Molecular and cell models of biological effects of heavy ion radiation. Radiat Environ Biophys. 1995;34:67-72.
39. Balcer-Kubiczek EK, Harrison GH, Xu JF, Gutierrez PL. Coordinate late expression of trefoil peptide genes (pS2/TFF1 and ITF/TFF3) in human breast, colon, and gastric tumor cells exposed to X-rays. Mol Cancer Ther. 2002;1:405-415.
40. Balcer-Kubiczek EK, Zhang XF, Harrison GH, et al. Delayed expression of hpS2 and prolonged expression of CIPl/WAFl/SDIl in human tumour cells irradiated with X-rays, fission neutrons or 1 GeV/nucleon Fe ions. Int J Radiat Biol. 1999;75:529-541.
41. Woloschak GE, Chang LCM. Differential modulation of specific gene expression following high- and low-LET radiations. Radiat Res. 1990;124:183-187.
42. Woloschak GE, Chang-Liu CM. Modulation of expression of genes encoding nuclear proteins following exposure to JANUS neutrons or gamma-rays. Cancer Lett. 1995;97:169-175.
43. Lucke-Huhle C. Similarities between human ataxia fibroblasts and murine SCID cells: high sensitivity to gamma rays and high frequency of methotrexate-induced DHFR gene amplification, but normal radiosensitivity to densely ionizing alpha particles. Radiat Environ Biophys. 1994;33:201-210.
44. Woloschak GE, Shearin JP, Chang LCM. Effects of ionizing radiation on expression of genes encoding cytoskeletal elements: kinetics and dose effects. Mol Carcinog. 1990;3:374-378.
45. Woloschak GE, Chang LC, Jones PS, Jones CA. Modulation of gene expression in Syrian hamster embryo cells following ionizing radiation. Cancer Res. 1990;50:339-344.
46. Reedijk J, Lohman PH. Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl Sci. 1985;7:173-180.
47. Spitz DR, Phillips JW, Adams DT, Sherman CM, Deen DF, Li GC. Cellular resistance to oxidative stress is accompanied by resistance to cisplatin: the significance of increased catalase activity and total glutathione in hydrogen peroxide-resistant fibroblasts. J Cell Physiol. 1993;156:72-79.
48. Taatjes DJ, Fenick DJ, Gaudiano G, Koch TH. A redox pathway leading to the alkylation of nucleic acids by doxorubicin and related anthracyclines: application to the design of antitumor drugs for resistant cancer. Curr Pharm Des. 1998;4:203-218.
49. Kharbanda S, Huberman E, Kufe D. Activation of the jun-D gene during treatment of human myeloid leukemia cells with 1-beta-D- arabinofuranosylcytosine. Biochem Pharmacol. 1993;45:2055-2061.
50. Sakamoto KM, Bardeleben C, Yates KE, Raines MA, Golde DW, Gasson JC. 5′ upstream sequence and genomic structure of the human primary response gene, EGR-1/TIS8. Oncogene. 1991;6:867-871.
51. Elion GB. The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother. 1983;12(Suppl B):9-17.
52. Vincent-Salomon A, Rousseau A, Jouve M, et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer. 2004;40:1502-1508.